Amalgamated Financial’s Harvard Bioscience HBIO Stock Holding History

Amalgamated Financial’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$38K	Buy	+620	New	+$36.7K	﹤0.01%	2537

Other funds holding HBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Financial's HBIO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Harvard Bioscience (HBIO) in Q1 2022: 620 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #2537 among its holdings.

98 funds tracked by Wall St. Rank hold HBIO as of Q1 2022.

Amalgamated Financial held 620 shares of Harvard Bioscience worth $38K as of Q1 2022.
Harvard Bioscience was a new Amalgamated Financial position in Q1 2022.
Harvard Bioscience made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2537 holding.
98 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.